Novel Imaging Techniques for the Characterization of Musculoskeletal Tumors II
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCentral Hospital, Nancy, France
About this trial
This study aims at evaluating the value of various artificial intelligence based techniques to improve the characterization and image post-processing for patients with musculoskeletal tumors.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients suspected to have a bone or soft-tissue tumor referred for imaging for initial tumors characterization and staging.
Disqualifiers
Pregnancy
Breast feeding patients
Renal insufficiency
Contra indications to MRI or CT
Trial population
Patients with soft-tissue and bone tumors evaluated with MR and ultra-high resolution CT.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
MR imaging
Diagnostic testMedical imaging
Treatment groups
740 Participants
are divided into 2 treatment groupsGroup A: Soft-tissue tumors1 intervention
Group B: Bone tumors1 intervention
Trial outcomes
Primary outcomes
1
Lesion benignancy or malignancy
Histologic determination of lesion aggressiveness (benign versus malignant) on core biopsy material
Time frame
Performed up to 6 months after CT and Magnetic Resonance (MR) imagingSecondary outcomes
1
Sarcoma FNCLCC (fédération Nationale des Centres de Lutte Contre le Cancer) grade
Histologic grade of the sarcomas included in the study population with surgical resection material
Time frame
Performed up to 1 year after CT and MR imagingSponsors and contacts
Click on the lead sponsor to view all of their trials.
Central Hospital, Nancy, France
Lead sponsor
Lorraine Cancer Institute - ICL
Collaborator
Emille Gallé Surgical Center - CCEG
Collaborator
Diagnostic and Interventional Adaptative Imaging Laboratory - IADI
Collaborator
Source ClinicalTrials.gov